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Abstract
Leukocyte telomere length (TL) is considered a biomarker for biological aging. Shortened TL has been observed in many
complex diseases, including type 2 diabetes (T2DM). Lifestyle intervention studies, e.g. the Diabetes Prevention Study (DPS),
have shown a decrease in the incidence of T2DM by promoting healthy lifestyles in individuals with impaired glucose
tolerance (IGT). Our aim was to study in the DPS the influence of the lifestyle intervention on TL. TL was measured by
quantitative PCR-based method at two time points (N= 334 and 343) on average 4.5 years apart during the active
intervention and post-intervention follow-up. TL inversely correlated with age. Our main finding was that TL increased in
about two thirds of the individuals both in the intervention and in the control groups during follow-up; TL increased most in
individuals with the shortest TL at the first measurement. TL was not associated with development of T2DM, nor did lifestyle
intervention have an effect on TL. No association between insulin secretion or insulin resistance indices and TL was
observed. We did not detect an association between TL and development of T2DM in the DPS participants. It could be due
to all participants being overweight and having IGT at baseline, both of which have been found to be independently
associated with shorter leukocyte TL in some earlier studies. TL had no substantial role in worsening of glucose tolerance in
people with IGT. Our study confirms that leukocyte TL can increase with time even in obese people with impaired glucose
metabolism.
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Introduction
Both genetic and environmental factors contribute to the
development of type 2 diabetes (T2DM) [1]. It has been shown
that obese individuals with impaired glucose metabolism, who are
at increased risk of developing T2DM, can decrease their risk of
developing T2DM by lifestyle changes involving a healthy diet,
increased physical activity and moderate weight loss [2].
Telomeres are the regions at the ends of the chromosomes and
consist of DNA repeat sequence and associated proteins. It has
been suggested that leukocyte telomere length (TL) is a biomarker
of biological aging, which can be used to predict morbidity and
mortality [3]. Leukocytes are the most intensively studied cell type
due to their easy access, and TL dynamics in other tissues are not
characterized in similar detail. In humans, the strongest evidence
for leukocyte TL as a predictor of mortality comes from twin
studies [4,5]. In somatic cells, TL shortens at cell division, while in
stem cells TL is maintained by the telomerase enzyme [6]. It has
recently been understood that while overall TL shortens by age, at
the individual level TL is a dynamic feature, and TL can also
increase in leukocytes over time [7–9].
TL is a complex phenotype affected by genes [10–13] and
environmental factors, such as smoking [14] and physical activity
[15]. Accelerated telomere shortening occurs in certain monogenic
diseases associated with premature aging, including ataxia
telangiectasia, Werner’s syndrome, and Bloom’s syndrome [6].
In addition, shortened TL has been observed in a large number of
complex diseases, with replicated findings in cardiovascular
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diseases [16,17]. This implies that chronic age-related diseases
may be associated with aging process per se.
T2DM is known to shorten life expectancy compared with the
general population, mostly due to cardiovascular diseases [18,19].
T2DM has been recently shown to associate with shortened TL in
leukocytes [20–24] and monocytes [25]. Risk factors for T2DM
have also been associated with shorter TL in some studies [26,27].
In addition, telomerase deficiency has been shown to impair
glucose metabolism and insulin secretion [28].
It has been suggested that lifestyle changes, including a healthier
diet, moderate aerobic exercise, and stress management can
increase leukocyte telomerase enzyme activity [29]. However, it is
not known whether lifestyle changes affect leukocyte TL. We set to
investigate whether lifestyle changes in the DPS including weight
loss, increased physical activity and healthy diet affect leukocyte
TL. In addition, we studied telomere dynamics over the follow-up
period, and investigated the relationship between TL and insulin
secretion and resistance, and risk of developing T2DM.
Methods
Ethic Statement
The study protocol was approved by the Ethics Committee of
the National Public Health Institute (currently National Institute
for Health and Welfare) of Helsinki, Finland, and all participants
gave written informed consent.
Study Sample
Design of DPS. The DPS was a randomized, controlled,
multicenter study carried out in Finland between the years 1993
and 2000 (ClinicalTrials.gov NCT00518167). A total of 522
individuals with impaired glucose tolerance (IGT) were
randomized into either an intervention or control group in five
centers starting between the years 1993–1998. The study design
and methods of the DPS have been reported in detail elsewhere
[30,31]. The main inclusion criteria were as follows: BMI
.25 kg/m2, age 40–64 years, and IGT based on the mean
values of two OGTTs based on the World Health Organization
1985 criteria. The median length of the original randomized
intervention study was 4 years (range 1–6 years).
Program for the intervention group. The intervention
program has been described previously in detail [30,31]. Briefly,
the individuals in the intervention group were given individually
tailored dietary advice aiming at reducing weight and the intake of
total and saturated fat and increasing the intake of dietary fiber. In
addition, individuals in the intervention group also received
individual guidance to increase their level of physical activity. The
control group received general advice on the benefits of weight
reduction, physical activity and a healthy diet.
Glucose and Insulin Measurements
Glucose levels were measured locally by standard methods, and
the measurements were standardized by the central laboratory in
Helsinki [31]. Serum insulin was determined with a radioimmu-
noassay in the central laboratory in Helsinki (Pharmacia, Uppsala,
Sweden). To estimate insulin secretion and insulin sensitivity, we
calculated the ratio of total insulin area under the curve (AUC)
and total glucose AUC during the 0–30 min OGTT (AIGR0–30)
and the Matsuda index of insulin sensitivity (Matsuda ISI: 10,000/
square root of [fasting glucose x fasting insulin6[arithmetic mean
of glucose 6 arithmetic mean insulin during an OGTT]]) using
glucose and insulin concentrations from samples taken during an
OGTT at 0, 30, and 120 min. These data were available for the
visits between the years 1 and 4 of the active randomized study
period. Based on the known nonlinear relationship between insulin
secretion and insulin sensitivity we also adjusted, by regression
analysis, the log of AIGR0–30 by the log of the Matsuda ISI at each
year of the study to obtain insulin secretion independently of
insulin sensitivity.
TL Measurement
Sampling for DNA extraction aiming at TL studies were taken
at two occasions. The first sampling was taken between the years
1997 and 1998 (ranging from baseline (n = 27) to 4 years in the
study trial; mean of 1.2 years), and the second sampling, between
the years 2001 and 2002 (ranging from 1 to 7 years of follow-up
after the study had ended; mean of 1.5 years). DNA samples at
two time points were available from 378 individuals comprising of
380 intervention cases and 376 controls (498 females and
258 males).
DNA was extracted from peripheral blood leukocytes by salt
precipitation method. The relative telomere length was de-
termined from DNA by a quantitative real-time PCR-based
method [32,33] with the following modifications. ß-hemoglobin
was used as a single copy reference gene. PCR reactions were
performed separately for telomere and ß-hemoglobin in paired
384 well plates in which matched sample well positions were used.
A genomic DNA dilution series (0.5, 1.0, 2.0, 5.0, 10, 20 and
30 ng) was included in every plate to create a standard curve,
which was used to perform absolute quantification of each DNA
sample. Ten ng of DNA was used for each individual reaction.
Samples were randomized according to sex and intervention
group with an equal number on each plate. The first and the
second DNA sample of each individual were placed on the same
qPCR plate. Samples and standard dilutions were transferred into
384-well plates as triplicates using DNA Hydra 96 robot (Art
Robbins Instruments, Sunnyvale, VA, USA) and dried for 24 h at
+37uC. ß-hemoglobin qPCR mix included 300 nM Hgb1 primer
(59-GCTTCTGACACAACTGTGTTCACTAGC-39) and Hgb2
primer (59-CACCAACTTCATCCACGTTCACC-39) in a total
volume of 15 ml of iQ SyBrGreen supermix (Bio-Rad). The
reaction conditions were 95uC for 3 min followed by 35 cycles at
95uC for 15 s, 58uC for 20 s and 72uC for 20 s. Telomere qPCR
mix content was 270 nM tel1b primer (59-
CGGTTT(GTTTGG)5GTT-39) and 900 nM tel2b primer (59-
GGCTTG(CCTTAC)5CCT-39), 1% DMSO (Sigma), 0.2 mM of
each dNTP (Fermentas), 1.5 mM MgCl2 (Applied Biosystems
International), 5 mM DTT (Sigma), 0.2X SYBR Green I
(Invitrogen), and 1.25 U AmpliTaq Gold DNA polymerase
(Applied Biosystems International) in a total volume of 15 ml
AmpliTaq Gold Buffer II. The cycling conditions were 10 min at
95uC followed by 25 cycles at 95uC for 15 s and 54uC for 2 min.
Both reactions were performed with CFX 384 Real-Time PCR
Detection System (Bio-Rad, Hercules, CA, USA). Specific primer
binding was controlled by Melt-curve analysis.
To perform quality control we used the Bio-Rad CFX Manager
software v.1.6. At this point triplicates with amplification curve
standard deviation above 0.5 at the threshold level were omitted
(telomere N=17; ß-hemoglobin N=26). The number of wells
without any amplification was 23 for telomere reaction and four
for ß-hemoglobin reaction. The average correlation coefficient of
the standard curves was 0.997 for both the telomere and the ß-
hemoglobin reaction. The corresponding average PCR efficiencies
were 92.1% and 83.2%, respectively. All plates included five
genomic DNA control samples for the plate effect calibration and
for monitoring repeat measures correlation coefficient of variation
(CV). The control sample group means in every plate were
calculated for the calibrator values and these were used to adjust
Telomere Length in Diabetes
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the qPCR plate effect (ratio separately from telomere or ß-
hemoglobin reaction and specific calibrator). The T/S (telomere
to single copy gene intensity) ratios from calibrated values were
calculated to obtain the relative TL for the samples. The quantities
of the control samples were used for obtaining the CV values as
the ratio of the standard deviation to the mean, and those were on
average 7.0% for the telomere reaction, 7.5% for the ß-
hemoglobin reaction, and 14.2% for their ratio (T/S).
Statistical Analysis
Statistical analyses were performed with SPSS software version
18.0 (SPSS Inc., Chicago, IL) and visualized with SigmaPlot
version 9.0. If TL deviated over 3 standard deviations from the
mean, the sample was omitted as an outlier (N=14). The final
sample consisted of 677 samples with TL measurement (311
individuals with both time points). The relationship between the
study groups and TL was examined by Univariate GLM adjusted
for age, sex and also adjusted for TL at the first DNA sampling
when the change in TL over time was tested. The association of
TL with the risk of incident T2DM during a mean of 8.5 years of
follow-up after the first TL measurement, and after a mean of
5.5 years of follow-up after the second DNA sampling was assessed
by Cox proportional hazards regression models adjusted for age,
sex and randomization group, and also adjusted for TL at the first
DNA sampling when the change in TL over time was tested. For
this purpose, individuals already diagnosed with T2DM according
to WHO criteria [31,34] at the beginning of each follow-up were
excluded from the analyses. The results are described as the
respective hazard ratios (HR) for the risk of developing T2DM
during each of the respective follow-up periods according to a 1-
SD change in TL. The proportional hazard assumption was
evaluated and confirmed using the Schoenfeld residual which was
plotted against time for each of the models. A P value of ,0.05
was considered statistically significant.
Results
Correlation of TL with Age and Sex
As expected, relative TL correlated inversely with age at both
first and second DNA sampling (b=20.11, p = 0.06 and
b=20.14, p = 0.04, respectively; Figure 1). In the entire sample,
women had longer relative TL than men at both first (0.86 6 0.19
vs. 0.836 0.17, p = 0.09) and second (0.986 0.25 vs. 0.936 0.23,
P = 0.09) DNA sampling, but the finding did not reach statistical
significance even when adjusting for age and randomization group
(p = 0.14 and p= 0.08, respectively; Figure 1).
TL According to Randomization Group
There was no significant difference in the relative TL between
the intervention and control groups at the time of the first
(p = 0.31) or second sampling (p = 0.76) (Table 1). Adjustments for
the time (years) in the study or in the follow-up at sampling did not
change the results. Results were similar when participants with
T2DM during the randomized trial period or during the entire
follow-up were excluded (p = 0.36 and p= 0.86).
TL Change Over Time
The mean time period between the first and second sampling
was 4.5 years (Table 1). We calculated the yearly change in TL as
the TL at the second sampling minus the TL at the first sampling
divided by the time between the samplings. Surprisingly, relative
TL during this about 4.5 year period increased in about two thirds
of the individuals (Figure 2). The yearly change in TL depended
on the TL at the first measurement (r =20.39, p,0.001; Figure 3);
the individuals who had the shortest TL at the first measurement
showed the largest increase in TL. There was no difference in the
TL change rate between the intervention and control groups
(p = 0.65; Table 1). Exclusion of individuals diagnosed with T2DM
during the randomized trial phase (first DNA sampling) did not
change the results (p = 0.49).
TL and BMI
Considering the individuals who had TL measured at both
DNA sampling, there was a slight increase in BMI between the
measurements within the average of 4.5 years (mean 6 SD: 30.4
6 4.5 vs. 30.9 6 4.9 kg/m2), which was not statistically different
between the study groups (p = 0.11, Table 1). In simple correlation
analyses, we did not find any correlation between BMI and the
relative TL at first or second DNA sampling (r = 0.01, p = 0.83 and
r = 0.03, p = 0.55, respectively). However, there was an inverse but
weak correlation between yearly change in TL and change in BMI
between the first and second DNA sampling (r =20.12, p = 0.03),
but after adjusting for age at sampling, sex, study group, and TL at
first DNA sampling using multiple linear regression model the
association was slightly attenuated (b=20.11, p = 0.06).
TL and T2DM
Over a mean of 8.5 years of follow-up (range 0.5 to 12.7 ) after
the first DNA sampling, 130 of the 302 participants developed
T2DM (5.1 per 100 person-years). Considering only individuals
whose second DNA sample was also available, during these 8.5
years, 118 of 282 participants developed T2DM (5.0 per
100 person-years). In participants whose TL was measured only
at the second DNA sampling, over a mean of 5.5 follow-up years
(range 0.2 to 8.2 years) after the second DNA sampling has been
taken, 66 of 245 participants developed T2DM (4.9 per
100 person-years).
In Cox regression models, we observed an inverse association
between the increase in TL over the 4.5 years and T2DM
development during the 8.5-year follow-up, although it was of
borderline significance (HR: 0.81 [0.65; 1.00]; p = 0.05). The TL
at the time of the first sampling and second DNA sampling,
however, were not significantly inversely associated with the risk of
developing overt T2DM during the 8.5 and 5.5 follow-up years,
respectively (HR: 0.46 [0.18; 1.16]; p = 0.10 and (HR: 0.76 [0.49;
1.18]; p = 0.22, respectively).
We also tested if TL was related to Matsuda insulin sensitivity
index (ISI) or to Matsuda ISI-adjusted AIGR0–30 as an estimate of
b-cell function, as both indices have been shown to be associated
with the risk of developing T2DM among the DPS participants
[35]. The positive correlation between the yearly change in TL
(r = 0.10) or TL at the first (r = 0.03) or second (r = 0.10) DNA
sampling were not significantly associated with the average
Matsuda ISI (4.03 6 1.93) during the four-year study follow-up
(p = 0.15, p = 0.57 and p= 0.09, respectively). We did not find any
correlation between the Matsuda ISI-adjusted AIGR0–30 during
the four-year study follow-up (mean 6 SD: 30.3 6 10.1) and TL
at first or second sampling or the TL yearly change (r,0.05 and
p.0.40 for all).
Discussion
The association between TL and chronic diseases has mostly
been studied in cross-sectional settings. In some studies published
so far, a shorter leukocyte TL has been associated with T2DM or
its risk factors [20–28]. T2DM can be prevented by changes in
lifestyle in high-risk individuals as shown in the DPS [30,31].
Therefore, in this study, we set out to investigate whether
Telomere Length in Diabetes
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preventative measures affect leukocyte TL within the average
follow-up of 4.5 years. Participants were middle-aged overweight
people with IGT. They were randomized to either a usual care
control group or an intensive lifestyle intervention group.
As expected, age was inversely correlated with TL. In-
terestingly, we detected an increase in TL in about two thirds of
the DPS participants both in the intervention and in the control
group. Individuals who had the shortest TL in the first sampling
showed the greatest increase in TL. Increased leukocyte TL
over time has been observed recently in a few studies [7–9]. In
all of them, telomere attrition rate has depended on the initial
TL both at a 10-year [7,8] and 6-month [9] follow-up periods.
Figure 1. Telomere length as a function of age. Females are shown with red dots and males with blue dots, each dot representing one
individual. Regression lines for both groups are shown with the same color coding. A) the first DNA sample; B) the second DNA sample.
doi:10.1371/journal.pone.0034948.g001
Table 1. The Diabetes Prevention Study sample.
Characteristic Intervention cases Controls
Number of individuals (n) 190 188
1st DNA sample available (n) 162 172
2nd DNA sample available (n) 171 172
Women 64.7% 67.0%
Age at inclusion to the study (years) 55.83 (67.17) 55.45 (66.97)
Age at DNA sampling (years)
1st DNA sample 57.07 (67.06) 56.69 (66.98)
2nd DNA sample 61.58 (67.09) 61.17 (66.97)
Time between 1st and 2nd DNA sample (years) 4.56 (60.57) 4.53 (60.68)
Relative telomere length
1st DNA sample 0.84 (60.18) 0.86 (60.18)
2nd DNA sample 0.96 (60.23) 0.97 (60.26)
Telomere length yearly change, n 0.027 (60.052), 150 0.022 (60.048), 161
BMI (kg/m2)
1st DNA sample 29.8 (64.2) 30.8 (64.7)
2nd DNA sample 30.4 (64.9) 31.2 (65.1)
Change (between 1st and 2nd DNA sampling) 0.49 (26.10; 8.77) 0.46 (25.57; 9.06)
Data are number of individuals, mean 6 SD, median (range) or %.
doi:10.1371/journal.pone.0034948.t001
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Therefore, it seems that individual leukocyte TL is a dynamic
feature and that TL can vary to both directions during a lifetime
[9].
Our main finding was an increase in the TL over the 4.5 year
follow-up period both in the intervention and in the control group.
This is most likely due to both groups receiving at least some
information regarding healthy lifestyle, although only the in-
tervention group was counseled and monitored intensively. Our
results suggest that TL may be linked to the progression from IGT
to T2DM. However, although the lifestyle intervention resulted in
a dramatic reduction in the risk of T2DM, it did not have any
differential effect on TL between the two groups. Again, since the
control group also received general information on a healthy
lifestyle, this may have diminished putative differences between the
groups. Telomere shortening is counteracted by the telomerase
enzyme. Ornish et al. [29] recently showed in men with benign
prostate cancer that a three-month intensive lifestyle change,
consisting of healthier diet, moderate aerobic exercise, stress
management, and group support sessions, increased telomerase
activity in peripheral blood mononuclear cells. Our study and
theirs are not easily comparable as TL was not measured by
Ornish et al. and telomerase activity was not measured in our
study.
In light of the fact that all participants had an increased risk for
T2DM, i.e. were overweight and had IGT, it is not surprising that
we did not see a stronger association with TL and T2DM
diagnosis. Obesity and IGT have themselves been associated with
shortened TL [14,28,36,37]. Another limitation in our study is the
lack of a population-based control group without any intervention.
Such controls would have enabled us to study in more detail the
effect of the intervention and the effect of development of T2DM
on TL. Also, despite that both DNA samples of an individual were
analyzed on the same qPCR plate for reliable measurement of TL
yearly change, we cannot rule out the effect of DNA storage period
on TL.
Figure 2. Telomere length change between the 1st and 2nd DNA sampling. Diabetes Prevention Study sample A) intervention cases and B)
controls as a histogram with frequencies of telomere length difference between two time points.
doi:10.1371/journal.pone.0034948.g002
Figure 3. Telomere length yearly change as a function of
telomere length at the 1st DNA sampling. Diabetes Prevention
Study sample intervention cases (N = 190) are shown with red dots and
controls (N = 188) with blue dots, each dot representing one individual.
Regression lines for both groups are shown with the same color coding.
Relative telomere length is adjusted for age and sex.
doi:10.1371/journal.pone.0034948.g003
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In conclusion, the lifestyle intervention with weight loss,
increased physical activity, and healthy diet did not have an
independent effect on TL since the TL was similar in the
intervention and control groups during the 4.5 year follow-up
period. However, TL may still play a role in the development of
T2DM. Finally, our study provides strong evidence that leukocyte
TL is a dynamic feature with the attrition rate correlating with the
initial TL, and this is also seen in middle-aged, overweight or
obese people with IGT.
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